HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First tuberculosis vaccine trial years begins

(Date:4/28/2015)... 2015 Foot and Ankle Specialists ... D. Palmer ( Annapolis and Clarksville Divisions ) ... at the Maryland Podiatric Medical Association meeting on April ... University in 1992 with a Bachelor of Arts in ... in intercollegiate soccer, track and cross-country. He then attended ...
(Date:4/27/2015)... 2015 Churchview Supportive Living, a Gardant ... Brunch and Fashion Show from 10:30 a.m. to noon ... at 2626 W. 63rd St. in Chicago, serves low-income ... help to maintain their independence. , “Mothers, grandmothers, godmothers ... Mother’s Day Brunch,” said Director of Marketing Elizabeth Clippard. ...
(Date:4/27/2015)... 28, 2015 Healthcare marketing specialists ... called “Website Anatomy 101.” Available for ... necessary design elements for a successful hospital website. ... design, user experience, search results and lead generation ... a well-designed website on patient volume and retention. ...
(Date:4/27/2015)... Tennessee (PRWEB) April 27, 2015 A variety ... help young people trapped in substance abuse. Programming for Jericho ... will serve girls, is launching this summer. , The first ... than $100,000 to serve adolescents. The Youth Town Jim Jackson ... Collierville on Monday, May 4, with tee times at 8 ...
(Date:4/27/2015)... 2015 "Understanding Mental Disorders: Your Guide ... by American Psychiatric Publishing, a division of the American ... at the National Press Club in Washington, D.C.. The ... by APA President Paul Summergrad, MD. Guest speakers will ... foreword to the book; Paul Gionfriddo, President and CEO ...
Breaking Medicine News(10 mins):Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2
(Date:4/27/2015)... , April 27, 2015 Harwood Feffer LLP ... board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or ... board has breached its fiduciary duties to shareholders. ... press release announcing results from its first Phase 3 ... release disclosed that in the trial, Rhopressa failed to ...
(Date:4/27/2015)... Bronstein, Gewirtz & Grossman, LLC is investigating ... of Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN ... Bronstein or his investor relations coordinator Eitan ... The investigation concerns whether Celladon and certain of ... 20(a) of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... 2015  Eiger BioPharmaceuticals, Incorporated today announced the presentation ... in patients with chronic hepatitis delta viral (HDV) infection. ... at Ankara University Medical School, Turkey ... LOWR HDV - 1 (LOnafarnib With and ... randomized subjects to receive different doses of lonafarnib with ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
Cached News: